ViroLogic plans further PhenoSense tests:
This article was originally published in Clinica
Executive Summary
ViroLogic, which manufactures the PhenoSense HIV drug resistance test, plans to commercialise a PhenoSense assay for entry inhibitors, a new class of anti-HIV drug, by the end of this year. The company says that research has shown that susceptibility to entry inhibitors varies widely among patients who have not yet been exposed to the drugs. ViroLogic, based in South San Francisco, California, is also planning to make a PhenoSense assay for viral fitness (ability to replicate) available for research use by the end of the year, and for clinical use in the first half of 2002.